Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
EHRA 25: The MORE-CRT MPP Trial
Author(s): Christophe Leclercq Added: 7 months ago
EHRA 2025 - Outcomes from cardiac resynchronization therapy (CRT) with MultiPoint pacing (MPP) to treat patients who are not responding to standard CRT show that MPP does not improve the conversion rate of non-responders to responders compared to standard CRT; however, a reduction in HF hospitalisation was seen in the group receiving MPP.Prof Christophe Leclercq (Centre Hospitalier Universitaire… View more

Electrophysiology & Arrhythmia
AHA 25: Beta-Blocker Therapy Post MI in Patients with Preserved LVEF
Author(s): Anna Meta Dyrvig Kristensen Added: 1 day ago
AHA Scientific Sessions 2025 – Dr Anna Meta Dyrvig Kristensen (Copenhagen University Hospital, Bispebjerg and Frederiksberg, DK) presents an individual patient data meta-analysis examining beta-blocker therapy after myocardial infarction in patients with preserved left ventricular ejection fraction.This comprehensive meta-analysis pooled individual patient data from five randomized controlled… View more

Heart Failure
AHA 25: CRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3
Author(s): Stephen Nicholls Added: 6 days ago
AHA 2025 - Phase 1 results show the CRISPR-Cas9 gene editing therapy is a safe treatment option targeting ANGPTL3 in patients with lipid disorders.Prof Stephen Nicholls (Monash Victorian Heart Institute, Clayton, AU) joins us to share results from a first-in-human phase 1 trial investigating a one-time infusion of CTX310, a CRISPR-Cas9 gene editing therapy, at different doses targeting… View more

Prevention & Chronic Conditions
The Evolving Treatment Landscape for HFpEF in Cardiac Amyloidosis
Author(s): Added: 6 days ago
Dr Sarah Cuddy (Brigham and Women's Hospital, US) joins us to discuss the role of non-disease modifying treatments including SGLT2 inhibitors, mineralocorticoid receptor antagonists, GLP-1 receptor agonists, and implantable hemodynamic monitors in cardiac amyloidosis, and what this means for managing heart failure in this unique patient population.Interview Questions:Can you provide an overview… View more

Heart Failure
Novel Therapies in ATTR-CM
Author(s): Michelle Dimza , Georgia Vasilakis , Justin L Grodin Added: 2 weeks ago

Heart Failure
Device Therapies in Heart Failure
Author(s): Yoel Benarroch , Natalie Tapaskar , Amin Yehya Added: 1 month ago

Heart Failure

Intervention
CRT 25: The PARTNER 3 Registry
Author(s): S. Chris Malaisrie Added: 7 months ago
CRT 25 - Dr S. Chris Malaisrie (Northwestern University, Evanston, US) joins us to discuss the five-year outcomes from the PARTNER 3 aortic valve-in-valve registry (NCT02675114). The prospective, randomized, multi-center study aimed to assess TAVR with the Edwards SAPIEN 3 transcatheter heart valve (Edwards Lifesciences) compared to aortic valve replacement with a commercially available surgical… View more

Intervention
CRT 24: SYNTAX: PCI With TAXUS and CABG in Complex Coronary Disease
Author(s): Patrick W Serruys Added: 1 year ago
CRT 2024 — Prof Patrick W Serruys (National University of Ireland, Galway, US) joins us to discuss learning from the SYNTAX trial.The SYNTAX trial is a randomized controlled trial designed to evaluate the efficacy and safety of percutaneous coronary intervention (PCI) with polymer-based paclitaxel-eluting TAXUS stents versus coronary artery bypass grafting (CABG) in patients with complex coronary… View more

Intervention

Vascular Disease and Surgery
CRT 25: Insights from the GUARD Study
Author(s): Baravan Al-Kassou Added: 8 months ago
CRT 25 - Insights on the progression risk in patients with mild to moderate aortic stenosis (AS) show that there was no significant difference in progression rates between mild and moderate AS. However, moderate AS patients had significantly higher mortality rates than mild AS patients at one- and two-year follow ups. The study also suggests that elevated phosphate levels and elevated… View more

Vascular Disease and Surgery
CRT 24: The ABSORB Trial
Author(s): David Power Added: 1 year ago
CRT 24 - We are joined in this short virtual interview by investigator, Dr David Power (Mount Sinai Hospital, US) to discuss the latest findings from the ABSORB trial series, revealed in 2024 at the CRT conference.ABSORB III is a prospective, randomized, single-blind, multicenter trail aiming to support the pre-market approval of the Absorb bioresorbable vascular scaffold (Abbott) for the… View more

Intervention

Vascular Disease and Surgery